Oridonin Inhibits SARS‐CoV‐2 by Targeting Its 3C‐Like Protease
Baisen Zhong(Sun Yat-sen University), Weiyu Peng(Chinese Academy of Sciences), Shan Du(Sun Yat-sen University), Bingyi Chen(Sun Yat-sen University), Yajuan Feng(Sun Yat-sen University), Xinfeng Hu(Sun Yat-sen University), Qi Lai(Sun Yat-sen University), Shujie Liu(Sun Yat-sen University), Zhong‐Wei Zhou(Sun Yat-sen University), Pengfei Fang(Shanghai Institute of Organic Chemistry), Wu Yan(Capital Medical University), Feng Gao(Chinese Academy of Sciences), Huihao Zhou(Sun Yat-sen University), Litao Sun(Sun Yat-sen University)
Cited by 26Open Access
Abstract
Oridonin Inhibits SARS-CoV-2 Oridonin, a natural product extracted from Rabdosia rubescens, possesses a wide range of pharmacological properties, including anti-inflammatory, anti-cancer, anti-microbial, neuroprotection, immunoregulation, etc. In article number 2100124, Baisen Zhong, Litao Sun, and co-workers demonstrate that Oridonin targets the SARS-CoV-2 3CL protease by covalently binding to cysteine145 in its active pocket to exert an anti-SARS-CoV-2 effect, which provides a novel candidate for the treatment of COVID-19.
Related Papers
No related papers found
Powered by citation graph analysis